Company profile
Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OK-432 | phase3 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07480356 | phase3 | recruiting | 2026-05-29 | 2028-04-01 | Protara Therapeutics | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer |
| NCT05871970 | phase2 | recruiting | 2023-10-18 | 2026-12-01 | Protara Therapeutics | Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
| NCT05951179 | phase2 | recruiting | 2023-09-15 | 2031-10-01 | Protara Therapeutics | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
| NCT05085977 | phase1 | completed | 2022-03-10 | 2024-09-03 | Protara Therapeutics | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
| NCT05085990 | phase1 | completed | 2023-05-08 | 2024-09-12 | Protara Therapeutics | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) |
FDA applications (0)
No records yet.